Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II-III sublingual immunotherapy in birch pollen allergy
2023-505567-37-00Phase 3Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Aug 2023
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of birch pollen allergen extract in birch pollen allergy and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Primary efficacy endpoint: Mean CSMS during PBPP. Started Aug 2023; status: completed.
02
Drugs
birch pollen allergen extract
03
Conditions
birch pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2023-505567-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505567-37-00.